Expression of BCL-6 and P-gp in Diffuse Large B-cell Lymphoma and Its Relationship with the IPI Index
-
摘要:
目的 通过免疫组化方法检测初诊弥漫大B细胞淋巴瘤（DLBCL）患者活检淋巴组织BCL-6、P-gp的表达，探讨初诊DLBCL患者上述指标表达的临床意义以及与IPI指数间的相关性。 方法 收集福建省立医院病理科存档的2006年10月~2010年10月，首次确诊DLBCL且接受化疗（CHOP或R-CHOP方案）≥2个疗程患者标本34例（其中27例完成6个疗程化疗），检测BCL-6、P-gp的表达。入选病例根据国际预后指数（IPI）进行评分，将评分结果分别与所检测指标的表达结果进行相关性分析；将患者2、6个疗程化疗疗效分别与IPI评分、BLL-6、P-gp表达进行分析。 结果 BCL-6、P-gp高表达与IPI评分密切相关，其中BCL-6高表达与IPI评分呈负相关，P-gp阳性表达与IPI评分呈正相关；2个疗程化疗疗效与IPI评分无相关性，与BCL-6高表达呈负相关，与P-gp呈正相关；6个疗程化疗疗效与BCL-6阳性表达呈负相关，与P-gp呈正相关。 结论 在初诊DLBCL患者中，BCL-6高表达与良好预后相关，P-gp高表达则提示预后不良。 Abstract:Objective To investigate the expression of BCL-6 and P-gp in DLBCL and to explore the relationship of BCL-6 and P-gp with the IPI index. Methods A total of 34 samples were obtained from the pathology department of Fujian provincial hospital. These samples were collected from DLBCL patients treated with more than two therapeutic courses. BCL-6 and P-gp expression, as well as their relationship with the patient prognosis were examined. Results BCL-6 and P-gp were closely related with the IPI score. BCL-6 was negatively while P-gp was positively correlated with the IPI score. The curative effects of two therapeutic courses had no relation ship with the IPI score but had a negative correlation with BCL-6 and a positive correlation with P-gp. The curative effects of six therapeutic courses had a negative correlation with BCL-6 and positive correlations with the IPI score and P-gp. Conclusion In DLBCL patients, high BCL-6 expression indicates better prognosis and high P-gp expression indicates poor prognosis. -
Key words:
- Diffuse large B-cell lymphoma /
- BCL-6 /
- P-gp /
- IPI score
-
图 1 DLBCL组织BCL-6阳性表达
A：出现棕黄色颗粒为阳性细胞（×100）；B：BCL-6阳性表达主要定位于细胞核（×400）
Figure 1. Expression of BCL-6 in DLBCL
图 2 DLBCL组织P-gp阳性表达
A：棕黄色颗粒为阳性细胞（×100）；B：P-gp阳性表达主要定位于细胞膜或胞浆（×400）
Figure 2. Expression of P-gp in DLBCL
表 1 BCL-6、P-gp与IPI评分关系 例
Table 1. Relationship of BCL-6 and P-gp with the IPI score
表 2 IPI评分、BCL-6、P-gp与2疗程化疗效果关系 例
Table 2. Relationship of BCL-6 and P-gp with the IPI score and curative effects of two therapeutic courses
表 3 IPI评分、BCL-6、P-gp与2疗程化疗效果Spearman检验结果
Table 3. Spearman test of the IPI score, BCL-6, P-gp, and curative effects of two therapeutic courses
表 4 IPI评分、BCL-6、P-gp与6个疗程化疗效果关系 例
Table 4. Relationship of BCL-6 and P-gp with the IPI score and curative effects of six therapeutic courses
表 5 IPI评分、BCL-6、P-gp与6疗程化疗效果Spearman检验结果
Table 5. Spearman test of the IPI score, BCL-6, P-gp, and curative effects of six therapeutic courses
-
[1] A predictive model for aggressive non Hodgkin's lymphoma. The International Non Hodgkin's lymphoma Prognostic Factors Project[J]. Nengl J Med, 1993, 329(9): 987-994. http://ci.nii.ac.jp/naid/10012117549 [2] 陈晓霞. Bcl-6与弥漫大B细胞淋巴瘤的相关性[J]. 国外医学肿瘤学分册, 2004, 31(12): 952-955. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZL200412024.htm [3] Berglund M, Thunberg U. Evaluation of immunophetype in diffuse large B-cell lymphoma and its impact on prognosis[J]. Mod Pathol, 2005, 18(8): 11-13. [4] Izidore SL, Ronald L. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5noncoding regulatory region of the BCL-6 gene[J]. Blood, 2000, 96(2): 635-639. doi: 10.1182/blood.V96.2.635 [5] Pooja A, Nuttapong N, Sulada P, et al. The expression of bcl-6 in diffuse large B cell lymphoma(DLBCL) is associated with improved progression free survival and overall survival following front-line Rituximab-chemotherapy. Blood(ASH Annual Meeting Abstracts) 2010, 116: Abstract 5073. [6] Jane N, Edie A, Sandra J, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006 vol. 107 no. 11 4207-4213. [7] Ponzoni M, Ferreri AJ, Pruneri G, et al. Prognostic value of BCL-6, CD10 and CD38 immunoreactivity in stage Ⅰ-Ⅱ gastric lymphomas, identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome[J]. Cancer, 2003, 106(2): 288-291. [8] 揭伟. 非霍奇金淋巴瘤中Bcl-6的表达及意义[J]. 广东医学院学报, 2003, 21(3): 210-212. doi: 10.3969/j.issn.1005-4057.2003.03.005 [9] Muramatsu M, Akasaka T, Kadowaki N, et al. Rearrangement of the BCL-6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL-2 rearrangement[J]. Br J Haematol, 1996, 93(4): 911-920. doi: 10.1046/j.1365-2141.1996.d01-1728.x [10] Yuen AR, Sikic BI. Multidrug resistance in lymphomas[J]. J Clin Cncol, 1994, 12(11): 24539. http://www.ncbi.nlm.nih.gov/pubmed/7964963 [11] Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil[J]. J Clin Oncol, 1991, 9: 17-24. doi: 10.1200/JCO.1991.9.1.17 -
下载:
点击查看大图
计量
- 文章访问数: 45
- HTML全文浏览量: 2
- PDF下载量: 0
- 被引次数: 0
